Next Article in Journal
Solving Patient Allocation Problem during an Epidemic Dengue Fever Outbreak by Mathematical Modelling
Previous Article in Journal
Postcode Lottery in Healthcare? Findings from the Scottish National Comprehensive Geriatric Assessment in Secondary Care Audit 2019
Previous Article in Special Issue
An Elderly COVID-19 Patient with Community-Acquired Legionella and Mycoplasma Coinfections: A Rare Case Report
Article

Clinical Study on the Efficacy and Safety of Arginine Administered Orally in Association with Other Active Ingredients for the Prevention and Treatment of Sarcopenia in Patients with COVID-19-Related Pneumonia, Hospitalized in a Sub-Intensive Care Unit

1
Internal Medicine Ospedale del Mare di Napoli, 80100 Naples, Italy
2
Medicina d’Urgenza Ospedale del Mare di Napoli, 80100 Naples, Italy
*
Author to whom correspondence should be addressed.
Academic Editors: Pierpaolo Di Micco and Anna Annunziata
Healthcare 2022, 10(1), 162; https://doi.org/10.3390/healthcare10010162
Received: 17 November 2021 / Revised: 3 January 2022 / Accepted: 5 January 2022 / Published: 14 January 2022
In order to evaluate the efficacy of oral supplementation with 3 g of arginine per day associated with creatine, L-carnitine, aspartic acid, magnesium, selenium and vitamins C and E (Argivit© Aesculapius Farmaceutici) in the prevention and treatment of sarcopenia in patients with COVID-19-related pneumonia, we conducted a parallel randomized study comparing it with standard therapy alone. Forty patients on standard therapy plus supplementation were compared with a control group of 40 patients, all hospitalized at the sub-intensive care unit of the Del Mare Hospital in Naples, with a clinical diagnosis of SARS-CoV-2 infection and COVID-19 pneumonia. Muscle strength was assessed with the handgrip test and muscle ultrasound. Arginine-supplemented patients had an average grip strength of 23.5 at the end of hospitalization compared with 22.5 in the untreated group with less reduction, showing statistical significance (p < 0.001). In the same way, the thickness of the vastus lateralis quadriceps femoris muscle measured at the end of hospitalization showed less reduction on ultrasound, with a higher average value in the group receiving treatment than in the group of patients without supplementation (p < 0.001). Upon discharge there was a 58.40% reduction in ventilation days in patients with arginine supplementation compared with the control group. View Full-Text
Keywords: COVID-19; SARS-CoV-2; arginine COVID-19; SARS-CoV-2; arginine
Show Figures

Figure 1

MDPI and ACS Style

Bologna, C.; Pone, E. Clinical Study on the Efficacy and Safety of Arginine Administered Orally in Association with Other Active Ingredients for the Prevention and Treatment of Sarcopenia in Patients with COVID-19-Related Pneumonia, Hospitalized in a Sub-Intensive Care Unit. Healthcare 2022, 10, 162. https://doi.org/10.3390/healthcare10010162

AMA Style

Bologna C, Pone E. Clinical Study on the Efficacy and Safety of Arginine Administered Orally in Association with Other Active Ingredients for the Prevention and Treatment of Sarcopenia in Patients with COVID-19-Related Pneumonia, Hospitalized in a Sub-Intensive Care Unit. Healthcare. 2022; 10(1):162. https://doi.org/10.3390/healthcare10010162

Chicago/Turabian Style

Bologna, Carolina, and Eduardo Pone. 2022. "Clinical Study on the Efficacy and Safety of Arginine Administered Orally in Association with Other Active Ingredients for the Prevention and Treatment of Sarcopenia in Patients with COVID-19-Related Pneumonia, Hospitalized in a Sub-Intensive Care Unit" Healthcare 10, no. 1: 162. https://doi.org/10.3390/healthcare10010162

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop